Actively Recruiting

Phase 1
Age: 12Months - 22Years
All Genders
NCT06894979

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Led by Children's Oncology Group · Updated on 2026-05-05

54

Participants Needed

20

Research Sites

145 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving AZD1390 with radiation may be safe, tolerable, and/or effective in treating pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma.

CONDITIONS

Official Title

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Who Can Participate

Age: 12Months - 22Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 12 months to less than 18 years for dose escalation phase and 12 months to less than 22 years for disease expansion phase
  • Newly diagnosed primary high-grade glioma, diffuse midline glioma (excluding primary spinal tumors), or diffuse intrinsic pontine glioma eligible for 54-59.4 Gy fractionated radiation
  • Histologic confirmation required except for typical DIPG
  • Patients with supratentorial tumors including various high-grade gliomas and non-pontine diffuse midline gliomas require histologic diagnosis
  • Patients with infratentorial tumors typical DIPG by imaging without histology or biopsy-proven high-grade gliomas
  • Measurable or non-measurable disease after surgery
  • Karnofsky score ≥ 50% for patients over 16 years, Lansky score ≥ 50% for 16 years and younger
  • No prior cancer therapy except surgery and/or corticosteroids with stable or decreasing steroid dose
  • Adequate blood counts and organ function within 7 days prior to enrollment
  • Ability to swallow whole tablets (no nasogastric or gastric tubes)
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding females; females of childbearing potential and males must use effective contraception during and after study as specified
  • Currently receiving other investigational drugs or anti-cancer agents except corticosteroids
  • Receiving anti-graft versus host disease medications post bone marrow transplant
  • Taking strong inhibitors or inducers of CYP3A4/5 enzymes
  • Received enzyme-inducing anticonvulsants within 14 days prior to enrollment
  • Uncontrolled infection or prior solid organ transplant
  • Unable to comply with safety monitoring or rapidly declining neurological status
  • Conditions affecting drug absorption (e.g., short gut syndrome), inability to swallow whole tablets
  • Known macular degeneration, uncontrolled glaucoma, cataracts
  • Primary spinal cord high-grade gliomas or metastatic disease
  • Gliomatosis involving at least 3 brain lobes except H3 K27M-mutant bithalamic tumors
  • Infant-type hemispheric high-grade gliomas or BRAFV600E mutations
  • History of prior radiotherapy as anti-cancer therapy
  • Presence of myopathy or elevated creatine kinase >5x upper limit of normal on two occasions
  • Clinically significant cardiac dysfunction or prolonged QTc >450 msec
  • Known hepatitis B or C with detectable viral load
  • Any medical condition compromising safety or study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

Children's Hospital of Alabama

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

Actively Recruiting

3

Children's Hospital of Orange County

Orange, California, United States, 92868

Actively Recruiting

4

UCSF Medical Center-Mission Bay

San Francisco, California, United States, 94158

Actively Recruiting

5

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Actively Recruiting

6

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

7

Children's Healthcare of Atlanta - Arthur M Blank Hospital

Atlanta, Georgia, United States, 30329

Actively Recruiting

8

Lurie Children's Hospital-Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

9

Riley Hospital for Children

Indianapolis, Indiana, United States, 46202

Actively Recruiting

10

C S Mott Children's Hospital

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

11

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

12

Washington University School of Medicine

St Louis, Missouri, United States, 63110

Actively Recruiting

13

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, United States, 10032

Actively Recruiting

14

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

15

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

16

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

17

Saint Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Actively Recruiting

18

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

19

UMC Cancer Center / UMC Health System

Lubbock, Texas, United States, 79415

Actively Recruiting

20

Seattle Children's Hospital

Seattle, Washington, United States, 98105

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here